UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):August 17, 2022

QLY BIOTECH GROUP CORP.

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-234137		98-1448750
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Carretera Turistica, Luperon, 12th km, No. 7, Grand Parada, Puerto Plata, Dominican Republic
(Address of principal executive offices)		(Zip Code)

(829) 947-5251

(Registrant’s telephone number, including area code)

Azar International Corp.

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered under Section 12(g) of the Exchange Act: None

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year.

On August 17, 2022, Azar International Corp. (the “Company”), amended its articles of incorporation change its name to QLY Biotech Group Corp. (the “Name Change”). The change was made in anticipation of entering into a new line of business operations. Also on August 17, 2022, the Company increased its authorized shares of common stock to 1,000,000,000.

Item 8.01. Other Events

On August 23, 2022, FINRA declared the Name Change. Also on July 28, 2022, the Company was informed by FINRA that the Company’s ticker symbol would be changed to LQLY in twenty business days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

3.1		Certificate of Amendment, filed with the Secretary of State of the State of Nevada on August 17, 2022.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 11, 2022

QLY BIOTECH GROUP CORP.

	/s/ Yang, Lixue
By:	YANG, LIXUE
Title:	CEO

QLY Biotech Group Corp. 8-K